Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | EQ |
---|---|---|
09:32 ET | 6010 | 1.79 |
09:36 ET | 110 | 1.794 |
09:56 ET | 700 | 1.79 |
10:06 ET | 600 | 1.79 |
10:15 ET | 329 | 1.7699 |
10:26 ET | 4079 | 1.7553 |
10:42 ET | 1000 | 1.77 |
10:57 ET | 100 | 1.76 |
11:06 ET | 442 | 1.765 |
11:29 ET | 742 | 1.75 |
12:07 ET | 485 | 1.7599 |
12:23 ET | 100 | 1.75 |
12:25 ET | 500 | 1.75 |
12:34 ET | 490 | 1.75 |
01:08 ET | 6403 | 1.74 |
01:19 ET | 500 | 1.75 |
01:33 ET | 7814 | 1.78 |
01:35 ET | 6811 | 1.8 |
01:37 ET | 100 | 1.82 |
02:06 ET | 300 | 1.7871 |
02:11 ET | 295 | 1.805 |
02:40 ET | 685 | 1.83 |
03:02 ET | 1100 | 1.8001 |
03:12 ET | 6984 | 1.76 |
03:14 ET | 6800 | 1.7649 |
03:18 ET | 1900 | 1.78 |
03:20 ET | 1685 | 1.765 |
03:21 ET | 611 | 1.76 |
03:23 ET | 1092 | 1.7899 |
03:27 ET | 1899 | 1.76 |
03:30 ET | 2599 | 1.76 |
03:34 ET | 8003 | 1.785 |
03:38 ET | 1413 | 1.78 |
03:41 ET | 2152 | 1.7673 |
03:43 ET | 1942 | 1.77 |
03:48 ET | 26307 | 1.76 |
03:50 ET | 100 | 1.79 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Equillium Inc | 60.6M | -4.7x | --- |
Microalliance Group Inc | 36.6M | 4.4x | --- |
CASI Pharmaceuticals Inc | 33.6M | -1.2x | --- |
Marinus Pharmaceuticals Inc | 79.1M | -0.5x | --- |
Biofrontera Inc | 7.6M | -0.1x | --- |
Health-Chem Corp | 1.2K | 0.0x | --- |
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $63.1M |
---|---|
Revenue (TTM) | $36.1M |
Shares Outstanding | 35.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.72 |
EPS | $-0.38 |
Book Value | $0.64 |
P/E Ratio | -4.7x |
Price/Sales (TTM) | 1.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40.24% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.